Cellectar Biosciences (CLRB)
(Delayed Data from NSDQ)
$3.02 USD
+0.50 (19.84%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $3.03 +0.01 (0.33%) 4:30 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Cellectar Biosciences, Inc. (CLRB) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$15.25 | $28.00 | $7.00 | 505.16% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Cellectar Biosciences, Inc. comes to $15.25. The forecasts range from a low of $7.00 to a high of $28.00. The average price target represents an increase of 505.16% from the last closing price of $2.52.
Analyst Price Targets (4 )
Broker Rating
Cellectar Biosciences, Inc. currently has an average brokerage recommendation (ABR) of 1.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, four are Strong Buy, representing 100% of all recommendations. A month ago, Strong Buy represented 100%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 4 | 4 | 4 | 4 | 4 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
6/20/2024 | Maxim Group | Jason Mccarthy | Strong Buy | Strong Buy |
3/28/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/4/2024 | Roth Capital Partners | Jonathan Aschoff | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.00 |
ABR (Last week) | 1.00 |
# of Recs in ABR | 4 |
Average Target Price | $15.25 |
LT Growth Rate | NA |
Industry | Medical - Products |
Industry Rank by ABR | 76 of 252 |
Current Quarter EPS Est: | -0.38 |